![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/c/c9/Momelotinib.svg/640px-Momelotinib.svg.png&w=640&q=50)
Momelotinib
Medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Momelotinib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Momelotinib, sold under the brand name Ojjaara, is an anticancer medication used for the treatment of myelofibrosis.[1] It is a Janus kinase inhibitor and it is taken by mouth.[1]
Quick Facts Names, Identifiers ...
![]() | |
Names | |
---|---|
Preferred IUPAC name
N-(Cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide | |
Other names
| |
Identifiers | |
| |
3D model (JSmol) |
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank |
|
KEGG | |
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C23H22N6O2 | |
Molar mass | 414.469 g·mol−1 |
Pharmacology | |
L01EJ04 (WHO) | |
By mouth | |
Legal status | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Close
Quick Facts Clinical data, Other names ...
Clinical data | |
---|---|
Other names | Momelotinib hydrochloride hydrate (JAN JP), Momelotinib dihydrochloride (USAN US) |
License data |
|
Identifiers | |
PDB ligand | |
CompTox Dashboard (EPA) |
Close
The most common adverse reactions include dizziness, fatigue, bacterial infection, hemorrhage, thrombocytopenia, diarrhea, and nausea.[4]
Momelotinib was approved for medical use in the United States in September 2023.[1][4][5] It was approved in the EU in January 2024.[6]